酒精使用障碍药物可促进酒精相关性肝硬化患者戒酒:系统评价与Meta分析结果
该系统评价与Meta分析检索PubMed、Embase和Scopus截至2022年5月的文献,纳入8项研究共794例酒精使用障碍合并肝硬化患者,其中仅4项随机对照试验进入Meta分析。结果显示,酒精使用障碍药物与降低饮酒率相关(相对风险=0.68,95%CI:0.48-0.97,P=0.03),较安慰剂或标准治疗提高戒酒率32%,异质性高(I²=67%);165例严重不良事件中仅5例(3%)可能与研究药物相关。作者结论认为这些药物在肝硬化患者中有效促进戒酒且安全性良好,但需更大规模研究,尤其是晚期肝病患者。
要点
- 酒精使用障碍药物与肝硬化患者饮酒率降低相关(相对风险=0.68,95%CI:0.48-0.97,P=0.03)。
- 与安慰剂或标准治疗相比,药物使戒酒率提高32%,异质性高(I²=67%)。
- 165例严重不良事件中仅5例(3%)可能与研究药物相关。
核心结论
- 酒精使用障碍药物在肝硬化患者中可有效促进戒酒,且安全性良好;但需更大规模研究,尤其是晚期肝病患者。
研究设计与样本
- 系统评价与Meta分析,遵循Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol指南,检索PubMed、Embase和Scopus截至2022年5月的文献。
- 共纳入8项研究、794例酒精使用障碍合并肝硬化患者,涉及4种酒精使用障碍治疗:巴氯芬(n=6)、美他多辛(n=1)、阿坎酸(n=1)和粪菌移植(n=1)。
- 纳入研究中4项为队列研究、4项为随机对照试验,仅随机对照试验进入Meta分析。
主要发现
- 酒精使用障碍药物与降低饮酒率相关(相对风险=0.68,95%CI:0.48-0.97,P=0.03),较安慰剂或标准治疗提高戒酒率32%,异质性高(I²=67%)。
- 安全性方面,165例接受酒精使用障碍药物治疗患者的严重不良事件中,仅5例(3%)可能与或很可能与研究药物相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 异质性高(I²=67%)。
- 需更大规模研究,尤其是晚期肝病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The role of medications for alcohol use disorder (MAUD) in patients with cirrhosis is not well established. Evidence on the efficacy and safety of these drugs in these patients is scarce. APPROACH AND RESULTS: We performed a systematic review and meta-analysis according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol guidelines on the efficacy of MAUD in patients with cirrhosis. A search was conducted in PubMed, Embase, and Scopus, including all studies until May 2022. The population was defined as patients with AUD and cirrhosis. The primary outcome was alcohol abstinence. Safety was a secondary outcome. We performed a random-effect analysis and expressed the results as relative risk of alcohol consumption. Heterogeneity was measured by I2 . Out of 4095 unique references, 8 studies on 4 different AUD treatments [baclofen (n = 6), metadoxine (n = 1), acamprosate (n = 1), and fecal microbiota transplant (n = 1)] in a total of 794 patients were included. Four were cohort studies, and 4 were RCTs. Only RCTs were included in the meta-analysis. MAUD was associated with a reduced rate of alcohol consumption [relative risk = 0.68 (CI: 0.48-0.97), P = 0.03], increasing alcohol abstinence by 32% compared to placebo or standard treatment, despite high heterogeneity ( I2 = 67%). Regarding safety, out of 165 serious adverse events in patients treated with MAUD, only 5 (3%) were possibly or probably related to study medications. CONCLUSION: MAUD in patients with cirrhosis is effective in promoting alcohol abstinence and has a good safety profile. Larger studies on the effects of MAUD are needed, especially in patients with advanced liver disease.
引用
- Gratacós-Ginès J, Bruguera P, Pérez-Guasch M, et al. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis. Hepatology. 2023. PMID: 37625154. doi:10.1097/HEP.0000000000000570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。